Dementia Today.net

Site updated at Wednesday, 22 June 2016

Living with Dementia

Amyloid Plaques

Alzheimer’s Disease Risk Factors

Age
Age is a risk factor for AD. The prevalence of AD doubles every five years after the age of 60.

Family history

A family history of AD is a consistent risk factor, and represents around a fourfold increase in the risk of developing the disease. It is thought that as many as… Alzheimer’s Disease Risk Factors   



Road Block as a New Strategy for the Treatment of Alzheimer’s

Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer’s. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception of Alzheimer’s disease, the amyloid beta precursor protein (APP) and the beta secretase enzyme (BACE1), follow a different path… Road Block as a New Strategy for the Treatment of Alzheimer’s   



Aging and Dementia: More Gray Hair and Less Gray Matter

The normal processes of the aging brain remain poorly understood, and some degree of memory loss is expected in usual senescence. Approximately 10% of the population over age 70 years will have significant memory loss, and at least half of these cases of dementia will be attributed to Alzheimer disease (AD). AD is perceived… Aging and Dementia: More Gray Hair and Less Gray Matter   



Researchers watch amyloid plaques form

Researchers at the University of Toronto Scarborough (UTSC) and Osaka University applied a new approach to take a close look at amyloid plaque formation, a process that plays important roles in Alzheimer’s disease. The technique would greatly aid the development and screening for novel therapeutics that can manipulate the formation of the toxic amyloid… Researchers watch amyloid plaques form   



Protein in the brain could be a key target in controlling Alzheimer’s

A protein recently discovered in the brain could play a key role in regulating the creation of amyloid beta, the major component of plaques implicated in the development of Alzheimer’s disease, according to researchers at Temple University’s School of Medicine.

A group led by Domenico Pratico, professor of pharmacology and microbiology and immunology at… Protein in the brain could be a key target in controlling Alzheimer’s   



FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   



New method may help detect marker for Alzheimer’s disease earlier

Use of a new drug to detect the beta-amyloid plaques in the brain that are hallmark signs of Alzheimer’s disease may help doctors diagnose the disease earlier, according to research that will be presented as part of the Emerging Science program (formerly known as Late-Breaking Science) at the American Academy of Neurology’s 64th Annual… New method may help detect marker for Alzheimer’s disease earlier   



$80 million research plan takes aim at Alzheimer’s

An $80 million national research plan to attack Alzheimer’s, a mind-robbing malady that may affect as many as 16 million Americans by 2050, will start this year with U.S.-sponsored studies on ways to prevent the disease in high-risk people and treat it with an insulin nasal spray.

The National Institutes of Health will spend… $80 million research plan takes aim at Alzheimer’s   



Amyloid imaging helps in evaluating possible Alzheimer disease

A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders. The journal is published by Lippincott Williams & Wilkins, a part ofWolters Kluwer… Amyloid imaging helps in evaluating possible Alzheimer disease   



Merck starts new trial to test Alzheimer’s drug

Merck & Co Inc has started a new trial of its experimental Alzheimer’s drug, the first mid-stage clinical trial of a promising new class of oral medicines that has the potential to shut down the production of a protein that many researchers believe is the primary cause of the disease.

The drugmaker said on… Merck starts new trial to test Alzheimer’s drug   



Team Unravels Central Mystery of Alzheimer’s

Scientists at The Scripps Research Institute (TSRI) have shed light on one of the major toxic mechanisms of Alzheimer’s disease. The discoveries could lead to a much better understanding of the Alzheimer’s process and how to prevent it.

The findings, reported in the April 10, 2013 issue of the journal Neuron, show that brain… Team Unravels Central Mystery of Alzheimer’s   



A second amyloid may play a role in Alzheimer’s disease, UC Davis researchers find

A protein secreted with insulin travels through the bloodstream and accumulates in the brains of individuals with type 2 diabetes and dementia, in the same manner as the amyloid beta Αβ plaques that are associated with Alzheimer’s disease, a study by researchers with the UC Davis Alzheimer’s Disease Center has found.

The study is… A second amyloid may play a role in Alzheimer’s disease, UC Davis researchers find   



Research suggests anti-inflammatory protein may trigger plaque in Alzheimer’s disease

Inflammation has long been studied in Alzheimer’s, but in a counterintuitive finding reported in a new paper, University of Florida researchers have uncovered the mechanism by which anti-inflammatory processes may trigger the disease.

This anti-inflammatory process might actually trigger the build-up of sticky clumps of protein that form plaques in the brain. These plaques… Research suggests anti-inflammatory protein may trigger plaque in Alzheimer’s disease   



Going Home (A short film on Dementia)

delirium8 - petersen1 - apraxia3 - alzheimer's research5 - body mass index2 - forms of dementia2 - management of delirium1 - cotard's syndrome1 - amyloid-beta peptides1 - alpha-synuclein proteins1 - amentia2 - hyperlipidemia1 - alzheimers disease center1 - functional activation studies1 - alzheimer's brain1 - synthetic tau fibrils1 - presenile-onset disease1 - brain functions in patients1 - neurodegeneration2 - amyloid beta 421 - risk of stroke1 - slowed movement1 - insomnia2 - parkinsonism1 - hormone replacement therapy1 - semantic dementia1 - long-term dementia1 - memory disorders program1 - cognitive functioning2 - difficulties with speech1 -